Should pre-transplant MRD be used to guide treatment in AML?

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Acute Lymphocytic Leukemia: Overview of Latest Guidelines in Hematological MalignanciesПодробнее

The prognostic impact of pre-transplant MRD-positivity in patients with AMLПодробнее

How can MRD guide treatment of AML?Подробнее

Using MRD to guide post-alloSCT treatment decisions in AMLПодробнее

Should patients with AML who are MRD-positive proceed to allogeneic stem cell transplantation?Подробнее

The role of pre-transplant MRD assessment in patients with AMLПодробнее

MRD in AML: prognoses, transplant and treatment planningПодробнее

Significance of Minimal Residual Disease in Acute Myeloid LeukemiaПодробнее

Should pre-transplant MRD be used to guide treatment in AML?Подробнее

Developments for the use of MRD in AMLПодробнее

How does pre-transplant MRD affect outcome in AML?Подробнее

Implementing MRD in clinical practice for patients with intermediate-risk AMLПодробнее

Using MRD to Guide Therapy in AMLПодробнее

MRD Monitoring in Acute Myeloid LeukemiaПодробнее

MRD in AML: What is it and what do I do about it?Подробнее

Integrating genomics and MRD in transplant decision-making for patients with AMLПодробнее

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDSПодробнее

Transplant indications in AMLПодробнее

Does current evidence support the use of MRD-guided treatment before transplant in AML?Подробнее

The importance of using MRD to guide treatment decisions in ALLПодробнее